Cerebral perfusion imaging evaluates pharmacologic treatment of unilateral moyamoya disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 8544009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Unilateral Moyamoya disease presents as unilateral stenosis or obstruction of the supraclinoid internal carotid artery, which causes cerebral hypoperfusion resulting in seizures or TIA-like attacks. In severe cases, surgical treatment is performed with superficial temporal artery-middle cerebral artery anastomosis. In mild cases, conservative management is the treatment of choice. Flunarizine is a calcium ion anti-blocking agent, whose primary effect is that the cerebral vessels have been used for the treatment of postcerebrovascular disorders. Recently, it has been suggested that flunarizine could be used to treat Moyamoya disease. This report documents the efficacy of flunarizine to improve regional cerebral perfusion in Moyamoya disease.
Medical subject headings
- Brain
- Calcium Channel Blockers
- Flunarizine
- Moyamoya Disease
- Organotechnetium Compounds
- Oximes
- Tomography, Emission-Computed, Single-Photon